- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05126251
Tangningtongluo Tablet for People With Prediabetes
Efficacy and Safety of Tangningtongluo Tablet in People With Prediabetes : a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Prediabetes is an intermediate transition to hyperglycemia between normal blood glucose and diabetes, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT)and the presence of a combination of the two.
At present, the prediabetes population in China is very large. Timely detection of this sub-health population and effective intervention are the key to prevent or delay diabetes and related complications. Basic research showed that Tangningtongluo had a good hypoglycemic effect on db/db diabetic mice and STZ induced diabetic rats, and could alleviate pancreatic islet destruction and insulin resistance to some extent.
In this study, the therapeutic effects of Tangningtongluo pian provided by Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd on patients with prediabetes was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Tangningtongluo pian in the treatment of prediabetes . In the design of this trial, the therapeutic effects and safety of Tangningtongluo pian in the treatment of prediabetes were evaluated with Tangningtongluo pian in the treatment group and placebo in the control group.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prediabetes is an intermediate transition to hyperglycemia between normal blood glucose and diabetes, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT)and the presence of a combination of the two.
At present, the prediabetes population in China is very large. Timely detection of this sub-health state and effective intervention are the key to prevent or delay diabetes and related complications. Prediabetes is mainly IGT, and its core pathophysiological basis is insulin resistance. The existing western medicine can improve insulin resistance to varying degrees, but it can not prevent diabetes. Tangning Tongluo is an in-hospital preparation of Guizhou bailing. It is used for diabetes caused by deficiency of Qi and Yin. The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome.Basic research showed that Tang Ning Tong Luo had a good hypoglycemic effect on db/db diabetic mice and STZ induced diabetic rats, and could alleviate pancreatic islet destruction and insulin resistance to some extent. In addition, the drug has a certain retarding effect on diabetic nephropathy animal models [renal function, renal pathology, urinary protein (3+ to 2+)] and fundus lesions, and also improves liver function and myocardial enzymes. Further mechanism studies show that Tangning Tongluo exerts its anti-inflammatory, hypoglycemic and obesity induced insulin resistance effects by up regulating the expression of sequence binding protein (SBP) 2 in macrophages ; In addition, mip1 was inhibited γ/ CCR1 axis improves in diabetic retinopathy.It is speculated that the drug may be effective for prediabetes In this study, the therapeutic effects of Tangningtongluo pian provided by Guizhou bailing Enterprise Group Pharmaceutical Co., Ltd on patients with prediabetes was evaluated clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was designed to provide evidence-based medical evidence for Tangningtongluo pian in the treatment of prediabetes .
In the design of this trial, the therapeutic effects and safety of Tangningtongluo pian in the treatment of prediabetes were evaluated with Tangningtongluo pian in the treatment group and placebo in the control group.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mei Han
- Phone Number: +86 13401131731
- Email: hanmeizoujin@163.com
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- Recruiting
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Jin Li, MD
- Phone Number: +865922137569
- Email: xdfyec@sina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- FPG 5.6mmol/L~6.9mmol/L or OGTT 2H blood glucose 7.8mmol/L~11.0mmol/L or HbA1c 5.7%~6.4%, the above 3 indicators need to meet at least 2 items;
- Age 18 ~ 70 years old (including boundary value);
- Patients who voluntarily signed the informed consent and had conditional follow-up.
Exclusion Criteria:
- Regularly take drugs affecting blood glucose within 1 month before screening, such as hypoglycemic drugs, glucocorticoids, niacin β- Adrenergic agonists, thyroid hormones, contraceptives, diazoxide, diuretics, phenytoin sodium γ- Interferon, etc;
- Combined with various diseases that may significantly shorten life expectancy, such as malignant tumors, severe organ failure and so on;
- Combined with various diseases that may seriously affect the subject's participation in the test, such as psychosis, serious motor system abnormalities, etc;
- Combined ALT or ast > 2.5 times the upper limit of normal value, or serum creatinine > 1.5mg/dl;
- Allergic to the test drug or its components;
- Pregnant or lactating women, or women who have pregnancy plans from the study period to 3 months after the last administration, or men who are unwilling to take a medically recognized effective non drug contraceptive measure.
- Chronic diarrhea caused by inflammatory bowel disease and irritable bowel syndrome;
- The investigator believes that it is inappropriate to be included in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Tangningtongluo group
|
Tangningtongluo Tablet is an in-hospital preparation of Guizhou bailing.
It is used for diabetes caused by deficiency of Qi and Yin.
The symptoms include thirst, drinking, overeating, polyuria, weight loss, shortness of breath, fatigue, hand, foot and heart heat and blurred vision; Type 2 diabetes and diabetic retinopathy see the above syndrome.
The present study shows that Tangningtongluo Tablet have certain hypoglycemic effects in diabetic animal models and diabetic patients, and may improve insulin sensitivity in diabetic mice.It is speculated that the drug may be effective for prediabetes.
(0.4g/tablet,Plate(12 pills/plate ×3 plates/box))
Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
|
PLACEBO_COMPARATOR: Placebo group
Placebo of Tangningtongluo tablet will be used in this arm. Patients should take medicine with warm water about 30min after meal. (2.0g/time, twice a day) According to the above usage and dosage, take 12 weeks continuously. After 12 weeks, the researcher decided whether the subjects entered the extended trial according to the wishes of the subjects, and continued to use the drug until 24 weeks. 2) Lifestyle intervention |
Avoid overeating, avoid large intake of high-calorie, high-fat foods, live a regular life, avoid sitting for a long time, strengthen exercise and reduce weight.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin sensitivity index
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
The change of Matsuda index value from baseline calculated according to three-point OGTT (0, 30min, 120min).
|
Baseline, 12weeks, 24weeks(if necessary)
|
Pancreatic β-cell function indicators
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
The change of Pancreatic β-cell function indicators from baseline according to insulin source index and insulin disposal index.
|
Baseline, 12weeks, 24weeks(if necessary)
|
HbA1c
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
The change of HbA1c from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Metabolic index
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of fasting blood glucose, OGTT 2H blood glucose,body weight, BMI, waist circumference, waist hip ratio, blood lipid (TC, TG, HDL-C, LDL-C), free fatty acid and blood uric acid from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Diabetes incidence rate
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Diabetes incidence rate of experimental group=Number of people diagnosed with diabetes/The sample size of experimental group Diabetes incidence rate of placebo group=Number of people diagnosed with diabetes/The sample size of placebo group
|
Baseline, 12weeks, 24weeks(if necessary)
|
The rate of blood glucose reversed to normal
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
The rate of blood glucose reversed to normal in experimental group=Number of people blood glucose reversed to normal/The sample size of experimental group The rate of blood glucose reversed to normal in placebo group=Number of people blood glucose reversed to normal/The sample size of placebo group
|
Baseline, 12weeks, 24weeks(if necessary)
|
Changes in the proportion of subjects diagnosed with fatty liver from baseline
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes in the proportion of the experimental group=The proportion of subjects diagnosed with fatty liver after treatment in the experimental group-The proportion of subjects diagnosed with fatty liver in the experimental group in baseline; Changes in the proportion of the placebo group=The proportion of subjects diagnosed with fatty liver after treatment in the placebo group-The proportion of subjects diagnosed with fatty liver in the placebo group in baseline;
|
Baseline, 12weeks, 24weeks(if necessary)
|
Vascular endothelial function indexes: PAI-1
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of PAI-1 from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Vascular endothelial function indexes: NO
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of NO from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Vascular endothelial function indexes: ET-1
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of ET-1 from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: TNF-α
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of TNF-α from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: IL-6
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of IL-6 from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: IL-2
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of IL-2 from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: IL-1β
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of IL-1β from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: adiponectin
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of adiponectin from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: hsCRP
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of hsCRP from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Inflammatory factor index: FGF-21
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of FGF-21 from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Urinary albumin creatinine ratio (UACR)
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of Urinary albumin creatinine ratio (UACR) from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
Incidence of diabetic retinopathy
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Incidence of diabetic retinopathy of experimental group=Number of people diagnosed with diabetic retinopathy/The sample size of experimental group Incidence of diabetic retinopathy of placebo group=Number of people diagnosed with diabetic retinopathy/The sample size of placebo group
|
Baseline, 12weeks, 24weeks(if necessary)
|
Carotid artery intima-media thickness
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of Carotid artery intima-media thickness measured by an ultrasound scanner from baseline
|
Baseline, 12weeks, 24weeks(if necessary)
|
The scores of prediabetes symptom questionnaire
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of the score of prediabetes symptom questionnaire from baseline .
This scale is self-made and includes 15 symptoms.
Each symptom scores 0-3 points, and the total score is 45 points.
The higher the score, the more severe the symptoms.
|
Baseline, 12weeks, 24weeks(if necessary)
|
The scores of short form health survey (SF-36)
Time Frame: Baseline, 12weeks, 24weeks(if necessary)
|
Changes of the MOS 36 item short form health survey (SF-36) scores from baseline,the minimum and maximum values of the survey are 156 and 37 respectively, and higher scores mean a better outcome.
|
Baseline, 12weeks, 24weeks(if necessary)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GZY-KJS-2021-006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prediabetes
-
Aga Khan UniversityLinnaeus University; Kenyatta UniversityRecruiting
-
Philip KernNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Chonbuk National University HospitalCompletedPreDiabetes
-
TNOWageningen University and Research; Google LLC.; Jumbo Supermarkten Bv.; Noldus...Completed
-
University of TorontoInternational Nut and Dried Fruit Council (INC); The National Dried Fruit Trade... and other collaboratorsUnknown
-
National Yang Ming UniversityRecruiting
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Clinical Nutrition Research Centre, SingaporeSingapore Institute for Clinical SciencesCompleted
-
Northwestern UniversityAllianceChicago; Erie Family Health CentersCompleted
-
Ohio UniversityTouro University, CaliforniaCompletedPreDiabetes
Clinical Trials on Tangningtongluo tablet
-
Affiliated Hospital of Nantong UniversityRecruiting
-
Guizhou Bailing Group Pharmaceutical Co LtdActive, not recruitingDiabetic Retinopathy | Type2 DiabetesChina
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
TakedaWithdrawn
-
Xgene Pharmaceutical GroupRecruiting
-
Abbisko Therapeutics Co, LtdCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical(Australia) Pty Ltd.Completed
-
Sequel Pharmaceuticals, IncTerminatedAtrial Fibrillation
-
Stallergenes GreerCompleted